Legal analysis assails FDA's lowering of standards for drug approval
The Brown University Psychopharmacology Update · 2026-04 · 37 (4) · 1-5
DOI: 10.1002/pu.31424 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.03.2026.
Abstract (Originalsprache)
The Food and Drug Administration's (FDA's) announcement last fall that it intends to approve a new indication for the folic acid derivative leucovorin signals a dangerous departure from long‐held evidentiary standards for drug approval, a group of legal and bioethics experts suggested in a published commentary. The authors wrote that the FDA has moved to approve leucovorin for some patients with autism despite having no evidence of benefit from any randomized controlled trial. Their viewpoint article was published online Dec. 22, 2025 in JAMA .
Zitieren
APA
(2026). Legal analysis assails FDA's lowering of standards for drug approval. The Brown University Psychopharmacology Update, 37(4), 1-5. https://doi.org/10.1002/pu.31424
Vancouver
Legal analysis assails FDA's lowering of standards for drug approval. The Brown University Psychopharmacology Update. 2026;37(4):1-5. doi:10.1002/pu.31424
BibTeX
@article{euvimed2026,
title = {Legal analysis assails FDA's lowering of standards for drug approval},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {4},
pages = {1--5},
doi = {10.1002/pu.31424}
}
EUVIMED